Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York
Mandate

Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York

October 17, 2019 Capital Markets and Public M&A

Vinge has advised Aprea Therapeutics, Inc. and its subsidiary Aprea Therapeutics AB in connection with its listing on Nasdaq, New York.

The initial public offering price was set to $15 and the biopharmaceutical company sold 6.5 million shares in the IPO to raise $97.75 million. Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing cancer therapeutics.

 
Vinge’s team has primarily consisted of Kristina Ekberg, Charlotte Levin, Maria Schultzberg, Anna Thoms and Stina Bengtsson.

Related

Vinge advises Stendörren in connection with issuance of green capital securities

 Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green capital securities in an amount of SEK 400 million (within a framework of SEK 800 million).
May 07, 2026

Vinge represents Cinven in connection with the acquisition of Ongoing Warehouse

 Vinge has represented the international private equity firm Cinven in connection with its acquisition of Ongoing Warehouse.
May 06, 2026

Vinge advises Fazer in connection with its acquisition of Aroma

 Fazer has entered into an agreement to acquire Konfektyrfabriken Aroma AB, a Swedish confectionery manufacturer known for its classic candy products such as Geléhallon, Hallonbåtar, Röda Hjärtan and Gräddkola. The acquisition strengthens Fazer's position in the Swedish confectionery market, particularly within pick & mix, packed candy, and seasonal products. The acquisition is subject to customary regulatory approvals.
May 06, 2026